Novo Nordisk (NYSE:NVO) is a leading global healthcare company based in Denmark, specializing in diabetes care and hormone replacement therapies. The company is a major player in the pharmaceutical industry, competing with giants like Pfizer and Sanofi. On October 1, 2025, HSBC set a price target of $70 for Novo Nordisk, suggesting a potential 18.3% increase from its current trading price of $59.17.
The stock saw a notable 6% increase by 11:30 a.m. on the same day, as highlighted by The Motley Fool. This surge is linked to an agreement between Pfizer and the Trump administration, which has raised hopes for similar deals for other pharmaceutical companies, including Novo Nordisk. The administration's initiative aims to boost pharmaceutical manufacturing in the U.S., potentially benefiting companies like Novo Nordisk.
President Donald Trump has threatened to impose 100% tariffs on branded or patented pharmaceutical products manufactured abroad and imported into the U.S. However, Pfizer's agreement includes a three-year grace period before these tariffs are enforced, provided the company increases its manufacturing investments in the U.S. This development has positively influenced Novo Nordisk's stock performance, despite it being a European company.
Currently, Novo Nordisk's stock is priced at $59.17, reflecting an increase of 6.63% or $3.68. Throughout the day, the stock fluctuated between a low of $55.74 and a high of $59.22. Over the past year, the stock has reached a high of $120.56 and a low of $45.05. Novo Nordisk boasts a substantial market capitalization of approximately $262.93 billion, with a trading volume of 23,038,027 shares on the NYSE.
